Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)

Federal funding opportunity PAR-25-326 from National Institutes of Health (Department of Health and Human Services).

Program funding history

Synopsis

Who can apply

• City or township governments
• Native American tribal organizations (other than Federally recognized tribal governments)
• Private institutions of higher education
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• For profit organizations other than small businesses
• Independent school districts
• County governments
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• Public and State controlled institutions of higher education
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Special district governments
• Native American tribal governments (Federally recognized)
• Public housing authorities/Indian housing authorities
• State governments
• Small businesses

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

The official record

Similar grants

• Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
  PAR-25-327 · National Institutes of Health · closes October 8, 2027
• Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
  PAR-24-293 · National Institutes of Health · closes August 18, 2027
• HEAL Initiative: Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins and the Nature of (PRECISION) Human Pain Network
  RFA-NS-26-013 · National Institutes of Health
• Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
  RFA-NS-26-001 · National Institutes of Health · closes November 10, 2026
• BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)
  RFA-MH-26-120 · National Institutes of Health · closes June 15, 2027
• Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
  PAR-25-122 · National Institutes of Health · closes November 16, 2027